Compare Stocks → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFNASDAQ:DFFNNASDAQ:ONCSNASDAQ:SEELNASDAQ:ZSAN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/ADFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsSEELSeelos Therapeutics$0.33$0.74$0.32▼$49.80$4.48M1.88427,947 shs383,013 shsZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%DFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-28.72%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-71.42%SEELSeelos Therapeutics-2.63%-25.30%-35.72%-73.08%-98.41%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.8833 of 5 stars3.24.00.00.00.60.00.0ZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0021,300.18% UpsideZSANZosano PharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/ASEELSeelos Therapeutics$2.20M2.03N/AN/A($3.42) per share-0.10ZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ADFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)ZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/ADFFNDiffusion PharmaceuticalsN/A10.7110.71ONCSOncoSec MedicalN/A0.890.89SEELSeelos TherapeuticsN/A0.140.14ZSANZosano PharmaN/A1.611.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/ADFFNDiffusion Pharmaceuticals9.95%ONCSOncoSec Medical8.69%SEELSeelos Therapeutics23.37%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/ADFFNDiffusion Pharmaceuticals1.80%ONCSOncoSec Medical1.32%SEELSeelos Therapeutics5.40%ZSANZosano Pharma2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableZSAN, ONCS, SEEL, ADDXF, and DFFN HeadlinesSourceHeadlineHOOK HOOKIPA Pharma Inc.seekingalpha.com - April 12 at 10:11 PMNachrichten - Weitere Nachrichtenwallstreet-online.de - January 9 at 2:39 PMLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planpbs.org - December 6 at 7:44 AMDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abn-tv.de - August 22 at 3:36 PMEast Bay Business Newsbizjournals.com - May 18 at 9:49 PMMankind Pharma IPO opens on April 25, listing scheduled for May 9moneycontrol.com - April 27 at 4:20 PMAstellas Pharmaforbes.com - April 6 at 12:00 PMGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundationfinance.yahoo.com - February 5 at 12:11 PMFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orderswashingtonexaminer.com - January 23 at 3:25 PMZosano Pharma Corporation (ZSANQ)ca.finance.yahoo.com - November 5 at 6:33 PMNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lillyendpts.com - October 13 at 11:22 AMBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giantsmsn.com - October 12 at 2:32 PMBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claimsmarketwatch.com - August 28 at 7:45 PMEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionbizjournals.com - August 27 at 4:10 PMZosano Pharma Corp (ZSANQ)investing.com - August 25 at 12:28 AMEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1Mbizjournals.com - July 26 at 8:27 PMA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.bizjournals.com - July 26 at 8:27 PMZosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8dbtnews.com - June 3 at 11:27 AMZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANmarketwatch.com - June 2 at 3:26 PMWhy Zosano Pharma Shares Are Getting Hammered Todaymsn.com - June 2 at 3:26 PMZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%seekingalpha.com - June 2 at 10:26 AMCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANmarketwatch.com - June 2 at 10:26 AMEast Bay migraine patch developer files for bankruptcybizjournals.com - June 2 at 10:26 AMZosano Pharma Files Voluntary Petition for Relief Under Chapter 11finance.yahoo.com - June 2 at 10:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Diffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Zosano PharmaNASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.